Yasodha Krishna Janapati

Yasodha Krishna Janapati

Auto-generated profile, based on publicly available information

Yasodha Krishna Janapati

School of Pharmacy & Health Sciences United States International University‐AFRICA (USIU‐A) Nairobi Kenya

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Animal Models and Experimental Medicine
Verified
Journal Article
Open access
YJYasodha Krishna Janapati
Yasodha Krishna Janapati
SJSunil Junapudi
Sunil Junapudi
Diabetes mellitus is one of the world's most prevalent and complex metabolic disorders, and it is a rapidly growing global public health issue. It is characterized by hyperglycemia, a condition involving a high blood glucose level brought on by deficiencies in insulin secretion, decreased activity of insulin, or both. Prolonged effects of diabetes include cardiovascular problems, retinopathy, neuropathy, nephropathy, and vascular alterations in both macro‐ and micro‐blood vessels. In vivo and in vitro models have always been important for investigating and characterizing disease pathogenesis, identifying targets, and reviewing novel treatment options and medications. Fully understanding these models is crucial for the researchers so this review summarizes the different experimental in vivo and in vitro model options used to study diabetes and its consequences. The most popular in vivo studies involves the small animal models, such as rodent models, chemically induced diabetogens like streptozotocin and alloxan, and the possibility of deleting or overexpressing a specific gene by knockout and transgenic technologies on these animals. Other models include virally induced models, diet/nutrition induced diabetic animals, surgically induced models or pancreatectomy models, and non‐obese models. Large animals or non‐rodent models like porcine (pig), canine (dog), nonhuman primate, and Zebrafish models are also outlined. The in vitro models discussed are murine and human beta‐cell lines and pancreatic islets, human stem cells, and organoid cultures. The other enzymatic in vitro tests to assess diabetes include assay of amylase inhibition and inhibition of α‐glucosidase activity.

10 June 2021
Verified
Book Chapter
Closed access
YJYasodha Krishna Janapati
Yasodha Krishna Janapati
SJSunil Junapudi
Sunil Junapudi
SDSudharshan Reddy Dachani
Sudharshan Reddy Dachani
Plant-based medicinal products have been acknowledged since ancient times. Several medicinal plants and their products have been used to control diabetes in the traditional therapeutic systems of many cultures worldwide. The plants provide a potential source of hypoglycemic drugs because many plants and plant-derived compounds have been used to treat diabetes. Several synthetic oral hypoglycemic agents are the primary forms of treatment for diabetes. However, prominent side-effects of such drugs are the main reason for an increasing number of people seeking alternative therapies that may have less severe or no side effects. Still, little toxicological information exists concerning traditional antidiabetic plants. The present paper attempts to list the plants with antidiabetic and related beneficial effects originating from different parts of the world and Polyherbal formulations. History has shown that medicinal plants have been used in traditional healing worldwide for a long time to treat diabetes. Such herbal plants have hypoglycemic properties and other beneficial properties, as reported in scientific literature. This book chapter portray, the importance of herbal plants and polyherbal formulations in the treatment of diabetes mellitus. The effects of these plants may delay the development of diabetes and its complications due to their chemical constituents.

1 January 2021
Verified
Book Chapter
Closed access
YJYasodha Krishna Janapati
Yasodha Krishna Janapati
SJSunil Junapudi
Sunil Junapudi
SDSudharshan Reddy Dachani
Sudharshan Reddy Dachani
Cancer is one of the prime rationales for mortality in humanity and remains a difficult disease to treat. Contemporary problems allied with conventional cancer chemotherapies embrace the insolubility of drugs in an aqueous medium, delivery of sub-therapeutic doses to target cells, lack of bioavailability, and most importantly, non-specific toxicity to normal tissues. Recent advances in nanotechnology investigation tackle potential solutions to these riddles. However, there are challenges regarding targeting specific sites, tracking the delivery system and control over the release of the drug to the target site. The nanodevices are 100 to 1000 times smaller than cells in humans; their size is comparable to the enzymes, the receptors. This enables them to have a large surface area and ability to interact with biomolecules on both the surface and inside cells. Nanomedicines between 8-100 nm have an enhanced permeability and retention (EPR) effect, which make these medicines to target passively the solid tumours.

1 December 2023 in Coronaviruses
Verified
Journal Article
Closed access
PDF file
SJSunil Junapudi
Sunil Junapudi
YJYasodha Krishna Janapati
Yasodha Krishna Janapati
SUSusmitha Uppugalla
Susmitha Uppugalla
THTimothy Harris
Timothy Harris
MYMUHAMMAD YASEEN
MUHAMMAD YASEEN
Muhammad LatifMuhammad Latif
Muhammad Latif
Background: Coronavirus is a zoonotic disease and transmits between animals and humans. The disease known as COVID-19 (SARS-CoV-2) has become a pandemic since its outbreak. In addition to vaccines, a combination of antiretroviral agents, chloroquine derivatives, and vitamins are being used to treat SARS-CoV-2. Method: We performed molecular docking analysis of SARS-CoV-2 inhibitor N3 (6LU7) using a series of flavonoid derivatives and vitamins. The X-ray crystallographic 3D structures of COVID-19 main protease in complex with an inhibitor N3 (PDB code: 6LU7, resolution 2.16 Å complexed with a selective substance) were downloaded from the online Protein Data Bank. The structures of the ligands and protein were constructed using ChemDrawUltra 8.0. The docking process, interactions, and binding of ligands were visualized using the software Molegro Virtual Dockings (MVD). The physicochemical and toxicity characteristics of tested flavonoid derivatives and vitamins were determined using Swiss-ADME and pkCSM online software. We found that molecular docking scores were between -64.42 and –172.00 Kcal/mol. The H-bonding and steric interactions were compared with other flavonoid derivatives. The ADMET parameters suggested that compounds 4, 68, 90, 92, and 94 have a higher GI rate. Results: Our results also indicated that compound 78 was more potent and had higher skin permeation than other flavonoid derivatives. The study showed that the compounds 5, 28, 74, 78, and folic acid fitted well in the active site of COVID-19 inhibitor N3 (6LU7) and interacted with the residues in the active site, which are essential for their biological activity. Conclusion: Therefore, compounds 5, 28, 74, and 78 and folic acid can be a COVID-19 inhibitor N3 (6LU7) and might be used in the treatment of COVID-19 infection.

20 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YJYasodha Krishana Janapati
Yasodha Krishana Janapati
MMMahesh M
Mahesh M
BPBochala Priyanka
Bochala Priyanka
KPK. Prema
K. Prema
Entacapone, essential for Parkinson’s therapy, requires stability-indicating assays to track degradation risks and maintain drug quality, safeguarding patient outcomes. Per ICH Q1A/Q2(R1), these methods must separate analytes from degradants during stress testing. We developed a streamlined RP-HPLC approach to address limitations in existing entacapone protocols. An Inertsil C18 column (50 × 4.6 mm, 5 μm) with 0.1% orthophosphoric acid: methanol (50:50, v/v) at 1.0 mL/min and 305 nm delivered linearity (2.5–7.5 µg/mL, r² = 0.9998), accuracy (98.7–101.2%), precision (%RSD <1.0%), robustness, and limits (LOD 0.5 µg/mL, LOQ 1.5 µg/mL). Stress degradation (acid, base, oxidation, heat, light, water) achieved full peak separation with purity compliance. It supports routine QC, assays, and stability monitoring per regulations. More widely, this demonstrates accessible analytical strategies for unstable drugs, promoting sustainable methods that enhance therapeutic reliability across medicine.